In a report released today, Daina Graybosch from SVB Securities maintained a Buy rating on Merck & Company (MRK – Research Report), with a price target of $105.00. The company's shares closed last Thursday at $89.94. According to TipRanks.com, Graybosch has 0 stars on 0-5 stars ranking scale with an average return of -17.1% and a 32.4% success rate. Graybosch covers the Healthcare sector, focusing on stocks such as Werewolf Therapeutics, Century Therapeutics, and Bolt Biotherapeutics. Merck & Company has an analyst consensus of Moderate Buy, with a price target consensus of $100.30, implying a 10.2% upside from current levels.
https://www.tipranks.com/news/blurbs/svb-securities-maintains-a-buy-rating-on-merck-company-mrk?utm_source=advfn.com&utm_medium=referral
Merck (NYSE:MRK)
Historical Stock Chart
Von Aug 2022 bis Sep 2022 Click Here for more Merck Charts.
Merck (NYSE:MRK)
Historical Stock Chart
Von Sep 2021 bis Sep 2022 Click Here for more Merck Charts.